Steven Mulackal Thomas
Research Subjects
Steven Mulackal Thomas has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Edward Sander Connolly
Department of Neurological Surgery, Columbia University Irving Medical Center, New York, New York, USA
2 shared publications- Austin R. Hoggarth
Virginia Tech Carilion School of Medicine, Virginia Tech, Roanoke, VA 24016, USA
1 shared publication Brandon Christophe
Department of Neurological Surgery, Columbia University Irving Medical Center, New York, USA
1 shared publicationBrandon R. Christophe
Department of Neurological Surgery, Columbia University Irving Medical Center, New York, New York, USA
1 shared publicationEllie Delanni
Department of Neurological Surgery, Columbia University Irving Medical Center, New York, USA
1 shared publication- Jackson W. Kiser
Carilion Clinic Radiology, Roanoke, VA 24016, USA
1 shared publication
Latest Publications
- Open Access
Clinical Theranostics in Recurrent Gliomas: A Review
Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of 12–18 months. While contrast-enhanced MRI serves as the standard diagnostic imaging modality for gliomas, it faces limitations in the evaluation of recurrent gliomas, failing to distinguish between treatment-related changes and tumor progression, and offers no direct therapeutic options. Recent advances in imaging modalities have attempted to address some of these limitations, including positron emission tomography (PET), which has demonstrated success in delineating tumor margins and guiding the treatment of recurrent gliomas. Additionally, with the advent of theranostics in nuclear medicine, PET tracers, when combined with therapeutic agents, have also evolved beyond a purely diagnostic modality, serving both diagnostic and therapeutic roles. This review will discuss the growing involvement of theranostics in diagnosing and treating recurrent gliomas and address the associated impact on quality of life and functional recovery.
Open AccessClinical Theranostics in Recurrent Gliomas: A Review
Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of 12–18 months. While contrast-enhanced MRI serves as the standard diagnostic imaging modality for gliomas, it faces limitations in the evaluation of recurrent gliomas, failing to distinguish between treatment-related changes and tumor progression, and offers no direct therapeutic options. Recent advances in imaging modalities have attempted to address some of these limitations, including positron emission tomography (PET), which has demonstrated success in delineating tumor margins and guiding the treatment of recurrent gliomas. Additionally, with the advent of theranostics in nuclear medicine, PET tracers, when combined with therapeutic agents, have also evolved beyond a purely diagnostic modality, serving both diagnostic and therapeutic roles. This review will discuss the growing involvement of theranostics in diagnosing and treating recurrent gliomas and address the associated impact on quality of life and functional recovery.
- 27 April 2022
- Published by Elsevier in World Neurosurgery
- Vol. 164, 41-63
Systematic Review of Resource Use and Costs in the Hospital Management of Intracerebral Hemorrhage
- 27 April 2022
- Published by Elsevier in World Neurosurgery
- Vol. 164, 41-63
Systematic Review of Resource Use and Costs in the Hospital Management of Intracerebral Hemorrhage
- 1 June 2021
- Published by Elsevier in American Heart Journal
- Vol. 236, 110-111
Re: Defect-free care trends in the Paul Coverdell National Acute Stroke Program, program, 2008–2018
- 1 June 2021
- Published by Elsevier in American Heart Journal
- Vol. 236, 110-111
Re: Defect-free care trends in the Paul Coverdell National Acute Stroke Program, program, 2008–2018
- 18 February 2021
- Published by Springer Nature in Neurological Sciences
- Vol. 42 (5) , 1705-1717
Systematic review of novel technology-based interventions for ischemic stroke
Purpose To identify novel technologies pertinent to the prevention, diagnosis, treatment, and rehabilitation of ischemic stroke, and recommend the technologies that show the most promise in advancing ischemic stroke care. Method A systematic literature search on PubMed and Medscape was performed. Articles were assessed based on pre-determined criteria. Included journal articles were evaluated for specific characteristics and reviewed according to a structured paradigm. A search on www.clinicaltrials.gov was performed to identify pre-clinical ischemic stroke technological interventions. All clinical trial results were included. An additional search on PubMed was conducted to identify studies on robotic neuroendovascular procedures. Results Thirty journal articles and five clinical trials were analyzed. Articles were categorized as follows: six studies pertinent to pre-morbidity and prevention of ischemic stroke, three studies relevant to the diagnosis of ischemic stroke, 16 studies about post-ischemic stroke rehabilitation, and five studies on robotic neuroendovascular interventions. Conclusions Novel technologies across the spectrum of ischemic stroke care were identified, and the ones that appear to have the most clinical utility are recommended. Future investigation of the feasibility and long-term efficacy of the recommended technologies in clinical settings is warranted.
- 18 February 2021
- Published by Springer Nature in Neurological Sciences
- Vol. 42 (5) , 1705-1717
Systematic review of novel technology-based interventions for ischemic stroke
Purpose To identify novel technologies pertinent to the prevention, diagnosis, treatment, and rehabilitation of ischemic stroke, and recommend the technologies that show the most promise in advancing ischemic stroke care. Method A systematic literature search on PubMed and Medscape was performed. Articles were assessed based on pre-determined criteria. Included journal articles were evaluated for specific characteristics and reviewed according to a structured paradigm. A search on www.clinicaltrials.gov was performed to identify pre-clinical ischemic stroke technological interventions. All clinical trial results were included. An additional search on PubMed was conducted to identify studies on robotic neuroendovascular procedures. Results Thirty journal articles and five clinical trials were analyzed. Articles were categorized as follows: six studies pertinent to pre-morbidity and prevention of ischemic stroke, three studies relevant to the diagnosis of ischemic stroke, 16 studies about post-ischemic stroke rehabilitation, and five studies on robotic neuroendovascular interventions. Conclusions Novel technologies across the spectrum of ischemic stroke care were identified, and the ones that appear to have the most clinical utility are recommended. Future investigation of the feasibility and long-term efficacy of the recommended technologies in clinical settings is warranted.
- 1 February 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (2) , 105493
Re: Patterns of Mechanical Thrombectomy for Stroke Before and After the 2015 Pivotal Trials and US National Guideline Update
- 1 February 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (2) , 105493
Re: Patterns of Mechanical Thrombectomy for Stroke Before and After the 2015 Pivotal Trials and US National Guideline Update